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N-terminal myristoylation can promote the association of proteins with the plasma membrane, a property
that is required for oncogenic variants of Src and Abl to transform fibroblastic cell types. The P210bcl/ab'
protein of chronic myelogenous leukemia cells is not myristoylated and does not stably transform NIH 3T3
fibroblasts; however, it will transform lymphoid and myeloid cell types in vitro and in vivo, suggesting that
myristoylation is not required for AbI variants to transform hematopoietic cells. To test this hypothesis, we
introduced point mutations that disrupt myristoylation into two activated Abl proteins, v-Abl and a deletion
mutant of c-Abl (AXB), and examined their ability to transform an interleukin-3-dependent lymphoblastoid
cell line, Ba/F3. Neither of the nonmyristoylated Abl proteins transformed NIH 3T3 fibroblasts, but like
P210#cr/a`b, both were capable of transforming the Ba/F3 cells to factor independence and tumorigenicity.
Nonmyristoylated Abl variants did not associate with the plasma membrane in the transformed Ba/F3 cells.
These results demonstrate that Abl proteins can transform hematopoietic cells in the absence of membrane
association and suggest that distinct functions of AbI are required for transformation of fibroblast and
hematopoietic cell types.
Numerous proteins, including the viral and cellular forms
of Src and Abl (2, 17, 38, 39), undergo myristoylation, a
cotranslational modification that entails removal of the first
methionine residue and attachment of a 14-carbon myristoyl
fatty acid moiety to the resulting N-terminal glycine (2, 29,
45). The N-terminal amino acid sequences of myristoylated
proteins share only limited homology. The only absolute
requirement is a glycine at the second position of the amino
acid sequence (42). Mutagenesis of the N terminus of Src
defines a short stretch of some six residues that is sufficient
to determine myristoylation (1, 4, 18, 31). These studies
demonstrate that myristoylation is involved in targeting the
Src protein to associate with the plasma membrane of cells
and that this function is critical for the capacity of Src to
transform fibroblast cell types (4). Membrane association
plays a similar role in the transforming function of Abl
protein variants. The myristoylated v-Abl protein of Abelson
murine leukemia virus transforms NIH 3T3 fibroblasts, but
the nonmyristoylated 210-kDa Bcr/Abl fusion protein(P210"cr/ab^) of chronic myelogenous leukemia cells does not
(7, 24). Interestingly, attachment of myristoylated Gag se-
quences to the N terminus of Bcr/Abl creates a Gag/Bcr/Abl
protein that efficiently transforms NIH 3T3 fibroblasts (7).
Though it fails to transform fibroblasts, P210bcr/ab' readily
transforms interleukin-3 (IL-3)-dependent hematopoietic
cells to growth factor independence and tumorigenicity (5,
13) and induces a variety of hematopoietic neoplasms in
mouse model systems (8, 9, 14, 15, 21). These observations
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suggest that myristoylation may not be as critical for trans-
formation of hematopoietic cell types as it is for fibroblasts.
To determine whether myristoylation is dispensable for
hematopoietic cell transformation, myristoylation-defective
mutants of v-Abl and a transforming SH3 deletion mutant of
c-Abl (AXB [17]) were assayed for their capacity to mimic
the biological activity of P210bcrlabl. Like p21jbcrabl neither
of the nonmyristoylated mutants transformed NIH 3T3
fibroblasts, but both retained the capacity to render the
IL-3-dependent lymphoblastoid cell line Ba/F3 (30) growth
factor independent and tumorigenic. The nonmyristoylated
variants of Abl did not associate with the plasma membrane
in Ba/F3 cells. These results suggest that myristoylation-
dependent plasma membrane association is necessary for
NIH 3T3 fibroblast transformation but not for the capacity of
Abl protein variants to transform hematopoietic cells.
MATERIALS AND METHODS
Constructs and cell lines. The constructs used in these
experiments were derivatives of the pucLJ retroviral vector
(Fig. 1). The cDNA inserts for type IV c-Abl, the N-termi-
nal type IV c-Abl deletion mutant AXB (17), v-Abl, and
P210cr/abl (5) have been described previously. A myristoy-
lation-defective mutant of v-Abl was made by oligonucle-
otide-directed mutagenesis of the glycine codon at amino
acid position number two of the Moloneygag p15 sequences
of v-abl. The GGC codon for glycine was mutated to GAC,
which specifies an aspartic acid residue, resulting in an
N-terminal glycine-minus mutant of the v-Abl protein (Gly-
v-Abl). In the same manner, a myristoylation-deficient mu-
tant of the N-terminal type IV c-Abl deletion mutant AXB
(17) was constructed by oligonucleotide-directed mutagene-
sis. The Gly- AXB construct is identical to wild-type AXB
except for a two-base-pair mutation in the second codon of
the abl sequence which specifies an alanine residue (GCT)
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FIG. 1. Constructs for the expression of Abl proteins. The pucLJ
vector is a derivative of pLJ (A. Korman and R. C. Mulligan,
Whitehead Institute). The pucLJ vector expresses a cDNA insert
from the 5' retroviral long terminal repeat (LTR) and a selectable
marker gene (neo, encoding resistance to the antibiotic G418) from
an internal simian virus 40 (SV) promoter. Coding sequences for
several Abl protein variants were cloned into the vectors for use in
expression studies in NIH 3T3 fibroblasts or IL-3-dependent Ba/F3
cells. These constructs are shown schematically to illustrate the
protein structures predicted for the cloned cDNA inserts. The
Gag/Bcr/Abl protein derives from a recombinant viral isolate (7) and
is shown here for structural comparison. A cloned facsimile has
been described elsewhere (44).
instead of glycine (GGG). Because of the absolute substrate
specificity of eukaryotic N-myristoyltransferases for N-ter-
minal glycine (41, 42), the Gly- v-Abl and Gly- AXB N
termini cannot be myristoylated. The constructs were as-
sayed for their capacity to transform NIH 3T3 fibroblasts by
one of the following two methods. Either constructs were
cotransfected with a plasmid specifying Moloney helper
virus (pZAP) onto NIH 3T3 cells, or a helper-free retroviral
producer line was generated and viral supernatant was used
to infect NIH 3T3 cells. Helper-free producer lines were
created by electroporating a linearized plasmid construct
into qi-2 cells (26) and selecting for stable integrants in G418
(1 mg/ml). The transfected or infected NIH 3T3 cells were
grown to confluence and scored for the appearance of
transformed foci after 14 days. Transformation was assessed
by the capacity to form foci of rounded, refractile cells above
a flat, confluent monolayer. For cells that appeared morpho-
logically transformed, anchorage-independent growth was
verified by the ability to form colonies when suspended in
semisolid medium containing Bacto-Agar (0.3%). Constructs
were introduced by electroporation into the IL-3-dependent
lymphoblastoid cell line Ba/F3 (30). For electroporation, 2 x
106 to 5 x 106 cells were washed and resuspended in 1 ml of
phosphate-buffered saline; 20 to 40 ,ug of linear plasmid
DNA in Tris-EDTA was added to the cells, and electropo-
ration was performed in a Bio-Rad Gene Pulser (960 ,uF, 250
mV). Electroporated cells were kept on ice for 5 min and
then transferred directly to growth media. Cells were grown
for 2 days prior to selection in G418 (2 mg/ml). G418-
resistant populations were washed twice in phosphate-buff-
ered saline and then split into media lacking a source of IL-3
in order to select for factor-independent growth. The criteria
for autonomous growth in the absence of IL-3 and tumori-
genicity in nude mice were previously described (5).
Immunoprecipitation. Cell lysates were incubated with
anti-Abl antisera (pEX4 and pEX5) and processed for an in
vitro immune complex kinase assay as previously described
(22). Immunoprecipitated proteins were displayed by sodium
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis
and visualized by autoradiography. Equivalent numbers of
cells were processed for each lane.
Immunofluorescence. Fibroblasts were grown on glass
coverslips and then fixed and permeabilized in methanol and
acetone as described previously (43). Ba/F3 cells were
pelleted onto coverslips by cytocentrifugation (Shandon
Instruments) and fixed in ethanol-acetic acid (3:1) for 15 min
at room temperature and then in 95% ethanol for 5 min at
room temperature, and then were air dried. The primary
antibody was a mixture of crude anti-Abl sera (pEX4 and
pEX5). The secondary antibody was a rhodamine-conju-
gated donkey anti-rabbit immunoglobulin G.
RESULTS
Nonmyristoylated Abl variants do not induce transformed
foci on NIH 3T3 fibroblasts. The myristoylated v-Abl protein
readily transforms NIH 3T3 fibroblasts (37), but expression
of the normal type IV c-Abl protein from a similar retroviral
context does not (10, 17). An internal deletion of 53 amino
acids near the N terminus of type IV c-Abl (called AXB) is
sufficient to generate a transforming Abl protein (17). The
AXB deletion maintains the N-terminal glycine of type IV
c-Abl and encodes a myristoylated protein. To determine
whether N-terminal myristoylation is required for Abl pro-
teins to transform NIH 3T3 fibroblasts, glycine-minus mu-
tants of the v-Abl and AXB proteins were introduced into
NIH 3T3 fibroblasts. Virus from helper-free retroviral pro-
ducer lines made with wild type v-abl caused the morpho-
logic transformation of NIH 3T3 cells (> 102 foci per ml), but
viral stocks made with the mutant Gly- v-abl construct
failed to induce focus formation upon infection of NIH 3T3
fibroblasts (<1 focus per ml; Table 1). Both the wild-type
and Gly- v-abl mutant viruses passed the marker for resis-
tance to the antibiotic G418 (approximately 4 x 104 G418
CFU/ml) and induced expression of a 160-kDa phosphopro-
tein in infected cells (data not shown). Expression of the
myristoylation-defective Gly- AXB protein in NIH 3T3 cells
likewise did not yield transformed foci (<1 focus per ,ug of
plasmid), in contrast with the myristoylated AXB construct,
which efficiently transformed NIH 3T3 fibroblasts (> 102 foci
per ,ug of plasmid). We experienced difficulty in isolating
nontransformed cell lines that expressed high levels of either
of the Gly- Abl proteins. However, as shown below, the
constructs specifying Gly- v-Abl and Gly- AXB express the
proteins efficiently in Ba/F3 cells.
Transformation of IL-3-dependent Ba/F3 cells by myristoy-
lated Abl protein variants. Constructs specifying various Abl
proteins were introduced into Ba/F3 cells by electroporation
(to avoid complications of retroviral recombination). Cell
lines resistant to the antibiotic G418 were isolated and tested
for their capacity to grow in the absence of growth factor.
Introduction into Ba/F3 cells of an empty vector specifying
resistance to G418 or one specifying the normal type IV
c-Abl protein yielded G418-resistant cell lines that retained
their dependence on exogenous IL-3 for growth. Previously,
it had been demonstrated that the v-Abl protein could render
Ba/F3 cells factor independent (27). In a similar manner,
Ba/F3 cells that express the AXB protein could be selected
to grow in the absence of IL-3. This factor-independent cell
line expressing AXB was tumorigenic in nude mice (Table 1).
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TABLE 1. Properties of NIH 3T3 fibroblasts and Ba/F3 cells
expressing Abl protein variants
Transforms Renders Ba/F3 Tumorigenic in nude
Protein NIH 3T3 cells factor mice" (no. of mice
cells' independentb with tumors/no.challenged)
c-Abl type IV No No No (0/5)
AXB Yes Yes Yes (3/3)
Gly- AXB No Yes Yes (2/2)
v-Abl Yes Yes Yes (9/9)
Gly- v-Abl No Yes Yes (3/3)
P21obcrlabl No Yes Yes (12/12)
a The properties of type IV c-Abl, AXR, and P210bcr/abl in fibroblasts (7, 17)
and of wild-type v-Abl and P210bcrlabl in Ba/F3 cells (5) were described
previously. For the wild-type v-abl, Gly- v-abl, and P210bcr/abl constructs,
focus-forming titers were compared in a helper virus-free system. In the
presence of helper virus, the Gly- v-abl construct underwent recombination
to yield small numbers of transformed foci that carried novel Gag/Abl fusion
proteins of altered size (data not shown), reminiscent of the generation of the
Gag/Bcr/Abl transforming variant (7).
b Electroporated Ba/F3 cells were first selected in G418 at 2 mg/ml and then
split into media lacking a source of IL-3 in order to select for factor-
independent cell growth. Cell lines from which no factor-independent clones
arose were weaned off IL-3 gradually in an attempt to select for clones with
intermediate requirements for IL-3. Only cell lines which proliferated in the
complete absence of exogenous IL-3 had a stable phenotype. By examining
conditioned medium from the factor-independent cell lines, it was determined
that none produced a growth factor that could support the proliferation of the
parental Ba/F3 cell line.
c Factor-dependent and -independent Ba/F3 cell lines were injected subcu-
taneously into nude mice as described previously (5). Animals were observed
for the development of large nonregressing malignant tumors. Cell lines were
considered nontumorigenic if the injected mice remained tumor-free for
several months.
Transformation of Ba/F3 cells by nonmyristoylated AbI
proteins. To determine whether myristoylation is required
for the ability of v-Abl and AXB to transform Ba/F3 cells,
constructs specifying Gly- variants of these proteins were
introduced into Ba/F3 cells. G418-resistant cell populations
were selected in media lacking a source of IL-3, and factor-
independent cell lines were obtained, each of which formed
tumors when injected into nude mice (Table 1).
AbI expression in Ba/F3 cell lines. Ba/F3 cell lines were
analyzed to determine whether Abl proteins of the predicted
size were being expressed. Cell extracts were immunopre-
cipitated with antisera directed against C-terminal Abl deter-
minants and processed for in vitro immune complex kinase
assay (22). Denaturing polyacrylamide gel electrophoresis
followed by autoradiography allowed for the detection of the
expected protein in each of the tested samples (Fig. 2). To
verify that the Gly- v-Abl protein expressed in factor-
independent Ba/F3 cell lines indeed lacked myristoylation,
Ba/F3 cell lines expressing Gly- v-Abl, P210bCr/abl, and
wild-type v-Abl were metabolically labelled with either
[35S]methionine or [3H]myristate, immunoprecipitated with
anti-Abl antisera, separated by denaturing polyacrylamide
gel electrophoresis, and analyzed by autoradiography. Cells
labelled with [35S]methionine expressed the relevant Abl
protein forms (Fig. 3A), but only the wild-type v-Abl protein
incorporated the [3H]myristate label (Fig. 3B). Incorporation
of [3H]myristate into the transforming protein was not de-
tected in the cells expressing the Gly- v-Abl or P210bcrlab'
protein, although twice as many cells expressing Gly- v-Abl
were labelled as for the wild-type v-Abl. Moreover, the
structure of the Gly- v-abl construct introduced into the
Ba/F3 cells was analyzed by Southern hybridization and
shown to be unrearranged (data not shown). These results
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FIG. 2. Immunoprecipitation analysis of Ba/F3 cell lines ex-
pressing Abl protein variants. Lanes (from left to right) contained
samples as follows. Uninfected Ba/F3 cells and a Ba/F3 cell line
expressing the type IV c-Abl protein were maintained in medium
supplemented with WEHI-3B conditioned medium as a source of
IL-3; Ba/F3 cell lines expressing the AXB, Gly- AXB, v-Abl, Gly-
v-Abl, and P210bcrlabl proteins were all factor independent and could
be maintained in media without added IL-3. The first two lanes were
taken from an independent experiment run under conditions com-
parable to those used for the other lanes. Sizes are shown in
kilodaltons.
indicate that the Gly- v-Abl protein expressed in Ba/F3 cells
lacks the myristoyl moiety. Myristoylation does not appear
to be required for Abl proteins to transform the hematopoi-
etic cell line Ba/F3.
Immunofluorescent localization of myristoylated and non-
myristoylated Abl proteins. The subcellular localization of
various myristoylated and nonmyristoylated Abl protein
forms was assessed by indirect immunofluorescence. When
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FIG. 3. Immunoprecipitation analysis of metabolically labelled,
factor-independent Ba/F3 cell lines. Cell lines expressing the Gly-
v-Abl (lane 1), P210tCr/a/) (lane 2), and wild-type v-Abl (lane 3)
proteins were labelled with either [35S]methionine for 4 h (A) or
[3H]myristate for 25 min (B) and processed for immunoprecipitation
analysis with anti-Abl antisera (pEX4 and pEX5). Twice as many
cells were processed for the Gly- v-Abl mutant than for samples in
the other lanes. Proteins were displayed by SDS-polyacrylamide gel
electrophoresis and visualized by autoradiography. Panel A was
exposed for 24 h. The prominent proteins of 116 and 140 kDa in
lanes 1 and 3 represent proteolytic breakdown products of the
160-kDa v-Abl protein frequently observed in these preparations.
The gel in panel B was soaked in Autofluor, dried, and exposed for
72 days. The arrow denotes the position of the 160-kDa
[3H]myristate-labelled v-Abl protein.
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expressed in NIH 3T3 fibroblasts, the nontransforming,
nonmyristoylated P210bcrlabl and Gly- v-Abl proteins local-
ized to the cytoplasm and were not detectably associated
with the plasma membrane (Fig. 4C and G). An association
of the P210bcr/abl protein with actin filaments was apparent,
as described previously (28, 43). The transforming, myris-
toylated Gag/Bcr/Abl and v-Abl variants, on the other hand,
associated in part with the plasma membrane (Fig. 4A and
E). These results argue that the presence of the myristoyl
moiety targeted a portion of the Abl protein to associate with
the plasma membrane in NIH 3T3 fibroblasts. To examine
the possibility that the various Abl proteins might localize
differently in hematopoietic cells, their subcellular distribu-
tion was determined in Ba/F3 cells. The myristoylated
proteins v-Abl and AXB were mainly cytoplasmic but asso-
ciated in part with the plasma membrane (Fig. 5A and C). By
contrast, the nonmyristoylated Gly- v-Abl, Gly- AXB, and
P21obcr/abl proteins showed only a cytoplasmic distribution
and lacked the prominent plasma membrane staining (Fig.
5B, D, and F).
DISCUSSION
Myristoylation and transformation. The nonmyristoylated
P210bcr/abl protein associated with human chronic myeloge-
nous leukemia readily transforms hematopoietic cell types in
culture and in animal model systems (6), suggesting that
myristoylation is not critical for the transforming activity of
Abl proteins in hematopoietic cells. To verify this hypothe-
sis, we created two nonmyristoylated point mutants of
transforming Abl proteins, Gly- v-Abl and Gly- AXB, and
showed that these forms behaved similarly to P210bcr/ablI
i.e., they failed to transform NIH 3T3 fibroblasts but re-
tained the capacity to transform the IL-3-dependent hema-
topoietic cell line Ba/F3. The subcellular localization of the
various myristoylated and nonmyristoylated Abl variants
argues that myristoylation targets some portion of the Abl
protein to associate intimately with the cell's plasma mem-
brane. The results presented above and in a previous study
(7) suggest that myristoylation is required for Abl protein
variants to transform NIH 3T3 fibroblasts. However, myris-
toylation-dependent membrane association appears irrele-
vant for transformation of hematopoietic cells.
Our attempts to generate stable nontransformed NIH 3T3
fibroblast cell lines that express high levels of the nonmyris-
toylated Gly- Abl variants proved unsuccessful, owing to
the known toxicity of Abl proteins (46). Thus, we cannot
rigorously exclude the possibility that myristoylation-defi-
cient forms of the Abl protein might transform NIH 3T3
fibroblasts if high enough levels of protein could be stably
achieved. However, we believe this to be unlikely, because
even high levels of the P210bCr/abl protein fail to transform
NIH 3T3 cells (7, 23). We are more compelled by the
likelihood that myristoylation-dependent membrane associ-
ation is critical for transformation of NIH 3T3 fibroblasts
because of the particular transformation requirements of this
adherent cell type. Alternatively, nonmyristoylated variants
may be inherently unstable in NIH 3T3 fibroblasts or more
stable in Ba/F3 cells. P210bcrIabl is weakly transforming for
Rat-1 fibroblasts (23). It would be interesting to determine
whether Bcr/Abl or other nonmyristoylated Abl variants
associate with the plasma membrane or are more stable in
Rat-1 cells, or whether distinct substrates are phosphory-
lated.
Role of membrane-associated and cytosolic forms of Abi in
transformation. Phosphorylation of membrane-associated
components that mediate contact inhibition may be critical
for the transformation of anchorage-dependent cell types
(16) and thus may be facilitated by targeting of transforming
protein kinases to the plasma membrane by myristoylation.
Integral membrane proteins that are phosphorylated only by
myristoylated Src variants have been identified by using
antisera directed against phosphotyrosine (12, 36). Other
candidate protein substrates include elements of signal trans-
duction pathways. Activated Abl proteins like P210bCr/abl,
Gag/Bcr/Abl, v-Abl, and AXB associate with a phos-
phatidylinositol 3'-kinase in fibroblasts, but only the mem-
brane-associated transforming variants lead to increased
steady-state levels of the 3'-phosphorylated lipid phosphati-
dylinositol trisphosphate (44), perhaps because of accessi-
bility to phospholipid substrates. Phosphatidylinositol tris-
phosphate levels correlate with mitogenesis in fibroblasts.
Activation of lipid kinase pathways may be one means by
which transforming Abl proteins undermine normal growth
control.
Factor-dependent hematopoietic cell types such as Ba/F3
grow in suspension culture and are not subject to the
constraints of contact inhibition. Instead, regulation of cell
proliferation in circulating hematopoietic cells occurs in
response to diffusible growth factors. By phosphorylating
some component of the IL-3 signal transduction pathway in
Ba/F3 cells, the Abl kinase may override the requirement for
exogenous growth factor and constitutively signal cell pro-
liferation. The critical substrate for transformation in this
case may be cytosolic and accessible to nonmyristoylated
forms of Abl. Interestingly, stimulation of cell proliferation
can be separated from transformation for nonmyristoylated
forms of Src. Nonmyristoylated Src proteins have mitogenic
activity for cells in culture, suggesting that the targets for
induction of cell proliferation are accessible to nonmyristoy-
lated Src protein (3, 19). Simply activating the Abl kinase
appears sufficient to transform Ba/F3 cells in the absence of
myristoylation-dependent membrane association. However,
it appears that two functions are necessary for transforma-
tion of NIH 3T3 fibroblasts: a kinase activity that activates
an intracellular mitogenic pathway, and membrane associa-
tion which enables the kinase to phosphorylate as yet
undefined membrane substrates in order to undermine con-
tact inhibition. Myristoylation provides one means of target-
ing Abl proteins to associate with the plasma membrane.
Fusion of the v-Abl kinase domain with the transmembrane
domain of the epidermal growth factor receptor provides
another such means and results in a protein that readily
transforms fibroblasts in culture (32).
Role of the myristoyl moiety in protein targeting. It is
unlikely that the hydrophobicity of the acyl moiety alone
mediates the association of myristoylated proteins with
membranes. A significant fraction of myristoylated proteins
can be found soluble in the cell (2, 25, 29). Moreover, the
association of the myristoylated alanine-rich C-kinase sub-
strate with the plasma membrane is reversibly regulated by
phosphorylation, and its distribution is concentrated in ad-
hesion plaques (40), arguing that the protein associates with
a specific receptor rather than through nonspecific insertion
of the lipid moiety in the membrane bilayer. Myristoylation
alone is not sufficient to specify the subcellular locale of Src.
Interestingly, Src associates chiefly with the plasma mem-
brane in fibroblasts but with other cellular membranes in
distinct cell types (e.g., growth cones in neurons). Certain
domains of the Src N terminus complement the myristoyla-
tion function in directing the protein to particular subcellular
locations (20). Myristoylation may serve as a ligand for
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FIG. 4. Indirect immunofluorescence of NIH 3T3 fibroblasts expressing Abl protein variants. (A) Transformed cells expressing the
myristoylated v-Abl protein; (B) nonimmune primary antiserum control for panel A. (C) nontransformed cells expressing the nonmyristoy-
lated Gly- v-Abl protein (analysis was performed on an unstable clone that was undergoing loss of expression of the Abl protein); (D)
nonimmune primary antiserum control for panel C; (E) transformed cells expressing the myristoylated P220 Gag/Bcr/Abl protein (7); (F)
nonimmune primary antiserum control for panel E; (G) nontransformed cells expressing the nonmyristoylated P210bcr/abl protein; (H)
nonimmune primary antiserum control for panel G. Note the accentuated membrane staining at areas of cell-cell contact in panels A and E.
membrane-associated receptors or docking proteins that
determine specific membrane destinations within the cell
(11, 33). In support of this notion, Resh (33, 34) and Resh and
Ling (35) have identified a plasma membrane myristoyl
receptor which binds the Src protein. Myristoylation appar-
ently targets only a portion of the type IV c-Abl protein in
the cell to associate with the plasma membrane. The stoi-
chiometry of myristoylation of Abl protein has not been
FIG. 5. Indirect immunofluorescence of Ba/F3 cells expressing Abl protein variants. (A) Myristoylated wild-type v-Abl protein; (B) non-
myristoylated Gly- v-Abl protein; (C) myristoylated AXB protein; (D) nonmyristoylated Gly- AXB protein; (E) parental Ba/F3 cells (control); (F)
nonmyristoylated P210o"61/ab protein. Note prominent membrane staining in panels A and C. Membrane staining is lacking in panels B, D, and F.
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determined, but it is highly plausible that myristoyl-Abl
receptors serve to partition Abl proteins in various compart-
ments within the cell. Myristoylation appears to be a neces-
sary but not sufficient signal for membrane localization, a
switch regulated in ways not yet understood.
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